Erratum: Pulmonary delivery of ISCOMATRIX influenza vaccine induces both systemic and mucosal immunity with antigen dose sparing (Mucosal Immunology (2008) vol. 1 (489-496) 10.1038/mi.2008.59);Pulmonary delivery of ISCOMATRIX influenza vaccine induces both systemic and mucosal immunity with antigen dose sparing

Mucosal Immunology

Volumn 1, Issue 6, 2008, Pages 489-496

  Wee, J L K ^a   Scheerlinck, J P Y ^a   Snibson, K J ^a   Edwards, S ^b   Pearse, M ^b   Quinn, C ^b   Sutton, P ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b CSL LIMITED   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; ISCOMATRIX; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; EXPERIMENTAL MODEL; FEMALE; IMMUNE RESPONSE; INFECTION RESISTANCE; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; MUCOSAL IMMUNITY; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; SHEEP; VIRUS HEMAGGLUTINATION;

EID: 54349124147     PISSN: 19330219     EISSN: None     Source Type: Journal    
DOI: 10.1038/mi.2008.76     Document Type: Erratum

References (33)

1. Rothberg, M. B., Haessler, S. D. & Brown, R. B. Complications of viral infl uenza. Am. J. Med. 121, 258-264 (2008).
2. www.cdc.gov/flu/about/fluviruses.htm.
3. Palache, A. M. Influenza vaccines. A reappraisal of their use. Drugs 54, 841-856 (1997).
4. Holmgren, J. & Czerkinsky, C. Mucosal immunity and vaccines. Nat. Med. 11, S45-53 (2005).
5. Waldman, R. H., Mann, J. J. & Small, P. A. Jr Immunization against influenza. Prevention of illness in man by aerosolized inactivated vaccine. JAMA 207, 520-524 (1969).
6. Lombry, C. et al. Local and systemic immune responses to intratracheal instillation of antigen and DNA vaccines in mice. Pharm. Res. 21, 127-135 (2004).
7. Pabst, R. & Gehrke, I. Is the bronchus-associated lymphoid tissue (BALT) an integral structure of the lung in normal mammals, including humans? Am. J. Respir. Cell Mol. Biol. 3, 131-135 (1990).
8. Nardelli-Haefliger, D. et al. Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. Vaccine 23, 3634-3641 (2005).
9. Menzel, M., Muellinger, B., Weber, N., Haeussinger, K. & Ziegler-Heitbrock, L. Inhalative vaccination with pneumococcal polysaccharide in healthy volunteers. Vaccine 23, 5113-5119 (2005).
10. Meyer, P., Menzel, M., Muellinger, B., Weber, N., Haeussinger, K. & Ziegler-Heitbrock, L. Inhalative vaccination with pneumococcal polysaccharide in patients with chronic obstructive pulmonary disease. Vaccine 24, 5832-5838 (2006).
11. Wigley, F. M., Wood, S. H. & Waldman, R. H. Aerosol immunization of humans with tetanus toxoid. J. Immunol. 103, 1096-1098 (1969).
12. Cocquyt, G., Baten, T., Simoens, P. & Van Den Broeck, W. Anatomical localisation and histology of the ovine tonsils. Vet. Immunol. Immunopathol. 107, 79-86 (2005).
13. Halmagyi, D. F. & Colebatch, H. J. Some cardiorespiratory parameters in anesthetized sheep. J. Appl. Physiol. 16, 45-47 (1961).
14. Chen, W., Alley, M. R. & Manktelow, B. W. Respiratory tract-associated lymphoid tissue in conventionally raised sheep. J. Comp. Pathol. 101, 327-340 (1989).
15. Scheerlinck, J. -P. Y., Snibson, K. J., Bowles, V. M. & Sutton, P. Biomedical applications of sheep models: From asthma to vaccines. Trends Biotechnol. 26, 259-266 (2008).
16. Drane, D., Gittleson, C., Boyle, J. & Maraskovsky, E. ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines. Expert Rev. Vaccines 6, 761-772 (2007).
17. Frazer, I. H. et al. Phase 1 study of HPV16-specifi c immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine 23, 172-181 (2004).
18. Davis, I. D. et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc. Natl. Acad. Sci. USA 101, 10697-10702 (2004).
19. WHO Infl uenza vaccines. Wkly. Epidemiol. Rec. 77, 230-240 (2002).
20. Johnson, N. P. & Mueller, J. Updating the accounts: Global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull. Hist. Med. 76, 105-115 (2002).
21. Kieny, M. P. et al. A global pandemic infl uenza vaccine action plan. Vaccine 24, 6367-6370 (2006).
22. Stephenson, I., Gust, I., Pervikov, Y. & Kieny, M. P. Development of vaccines against infl uenza H5. Lancet Infect. Dis. 6, 458-460 (2006).
23. Legrand, J., Vergu, E. & Flahault, A. Real-time monitoring of the influenza vaccine field effectiveness. Vaccine 24, 6605-6611 (2006).
24. Waldman, R. H. et al. An evaluation of influenza immunization: influence of route of administration and vaccine strain. Bull. World Health Organ. 41, 543-548 (1969).
25. Agu, R. U., Ugwoke, M. I., Armand, M., Kinget, R. & Verbeke, N. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir. Res. 2, 198-209 (2001).
26. Rosenstock, J., Muchmore, D., Swanson, D. & Schmitke, J. AIR Inhaled Insulin System: A novel insulin-delivery system for patients with diabetes. Exp. Rev. Med. Devices 4, 683-692 (2007).
27. Shoyele, S. A. & Cawthorne, S. Particle engineering techniques for inhaled biopharmaceuticals. Adv. Drug Deliv. Rev. 58, 1009-1029 (2006).
28. Clark, A. R., Chambers, C. B., Muir, D., Newhouse, M. T., Paboojian, S. & Schuler, C. The effect of biphasic inhalation profi les on the deposition and clearance of coarse (6.5 microm) bolus aerosols. J. Aerosol. Med. 20, 75-82 (2007).
29. Cassetti, M. C., Katz, J. M. & Wood, J. Report of a consultation on role of immunological assays to evaluate efficacy of influenza vaccines. Initiative for Vaccine Research and Global Influenza Programme, World Health Organization, Geneva, Switzerland, 25 January 2005. Vaccine 24, 541-543 (2006).
30. Oshitani, H. et al. Influenza vaccination levels and influenza-like illness in long-term-care facilities for elderly people in Niigata, Japan, during an influenza A (H3N2) epidemic. Infect. Control. Hosp. Epidemiol. 21, 728-730 (2000).
31. Langlois, R. A. & Legge, K. L. Respiratory dendritic cells: Mediators of tolerance and immunity. Immunol. Res. 39, 128-145 (2007).
32. Pearse, M. J. & Drane, D. ISCOMATRIX® adjuvant for antigen delivery. Adv. Drug Deliv. Rev. 57, 465-474 (2005).
33. Kendal, A. P., Pereira, M. S. & Skehel, J. J. Concepts and Procedures for Laboratory-based Influenza Surveillance, US Department of Health and Human Services, Public Health Service, Centers for Disease Control, Atlanta, (1982).